Home  |  Contact

Cellosaurus Rh41 (CVCL_2176)

Cell line name Rh41
Synonyms RH41; RH-41; Rh-41
Accession CVCL_2176
Resource Identification Initiative To cite this cell line use: Rh41 (RRID:CVCL_2176)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Doubling time: 44 hours (PubMed=20922763); ~2-3 days (DSMZ); 60 hours (COG).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Alveolar rhabdomyosarcoma (NCIt: C3749)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8670 (Rh41-807R)CVCL_8751 (Rh41-MAB391R)
Originate from same individual CVCL_5916 ! Rh4
Sex of cell Female
Age at sampling 7Y
Category Cancer cell line
STR profile Source(s): COG; Cosmic-CLP; DSMZ; PubMed=20922763

Markers:
AmelogeninX
CSF1PO11,12
D2S133817,21
D3S135817
D5S81810,13
D7S82010,11
D8S117910,13
D13S3178,9
D16S53912,13
D18S5115,16
D19S43313,15
D21S1129,31
FGA20,22
TH017,9.3
TPOX8,11
vWA16,18
Web pages http://www.cogcell.org/dl/Rh_DataSheets/Rh41_Cell_Line_Data_Sheet_COGcell_org.pdf
http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
Publications

PubMed=11051265
Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.
Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Clin. Cancer Res. 6:4119-4127(2000)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23882450; DOI=10.3389/fonc.2013.00183
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183-183(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections DSMZ; ACC-592
Cell line databases/resources CCLE; RH41_SOFT_TISSUE
Cosmic-CLP; 1240210
GDSC; 1240210
LINCS_LDP; LCL-1415
Biological sample resources BioSample; SAMN03473491
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM219748
GEO; GSM887538
GEO; GSM888621
GEO; GSM1670378
GEO; GSM1676313
GEO; GSM1701647
Other Wikidata; Q54950346
Polymorphism and mutation databases Cosmic; 1620039
Cosmic; 1718364
Cosmic; 1995621